CD274 and non-small cell lung carcinoma: In the following open-label phase 2 study, the efficacy and safety of nivolumab plus ‘low-dose’ ipilimumab as first-line treatment for metastatic NSCLC was tested and the association of efficacy with PD-L1 expression and tumor mutational burden was assessed.